For those that are interested. I did a bit of digging, I am not expert in the field, take it with a grain of salt. Judge for yourself.
Peptide receptor radionuclide therapy (PRRT)
- Needed therapy.
- Last line of defence.
- More monoclonal antibodies(mAB) treatment these days.
- CAR-T designer immunotherapy, better and targeted.
- Current approved treatment.
Copper
- Nice to have the same compound in treatment and diagnostic.
- Very little supply around the world.
- Cost is 10-15x more per dose than current therapy.
- Cost of transportation of radiation compounds very high, using specialised lead pot.
- Looking at the scan, the kidneys light up like a Christmas tree (I am not a medical expert, just my two cents’ worth).
- Special calibration needed for scan using copper, so very hard to share machine.
- Purity of Copper isotope from difference supplier
- Wave length of copper 67 attached to the peptide + linker close enough to cause cell death? (No expert just a question I have)
Peptide
- Can the production of peptide be produced to cGMP standard?
Remuneration
- The huge sum paid to the CEO and the chairperson + 40% bonus?
Clinical
- NCT04440956 – no results
- NCT03936426 – no results
- Priority Review Voucher – only available once the drug hit the market, so after phase III clinical trials and FDA review and approve the drug. You can have ten thousand Priority Review Vouchers, but unless a drug makes it to market after phase III, it is worth nothing.
Company
- More than 10 years old company.
I will leave It at that, again cancer treatment options are always needed, lots of player in the market, lots of approved therapy including PRRT.
- Forums
- ASX - By Stock
- CU6
- IPO - Clarity Pharmaceuticals Ltd - 25 August 2021 #
IPO - Clarity Pharmaceuticals Ltd - 25 August 2021 #, page-3
-
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CU6 (ASX) to my watchlist
|
|||||
Last
$4.85 |
Change
-0.390(7.44%) |
Mkt cap ! $1.511B |
Open | High | Low | Value | Volume |
$5.23 | $5.23 | $4.83 | $6.035M | 1.198M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 573 | $4.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.89 | 16349 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 219 | 5.090 |
1 | 7550 | 5.080 |
1 | 1 | 4.930 |
1 | 100 | 4.900 |
5 | 1137 | 4.850 |
Price($) | Vol. | No. |
---|---|---|
4.610 | 1000 | 1 |
4.800 | 3274 | 2 |
4.830 | 16921 | 2 |
4.840 | 119030 | 3 |
4.850 | 4288 | 4 |
Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online